- Home
- CMMB vs SNGX Comparison
CMMB vs SNGX Comparison
Compare CMMB & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- SNGX
- Stock Information
- Founded
- CMMB 2004
- SNGX 1987
- Country
- CMMB Israel
- SNGX United States
- Employees
- CMMB N/A
- SNGX N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- CMMB Health Care
- SNGX Health Care
- Exchange
- CMMB Nasdaq
- SNGX Nasdaq
- Market Cap
- CMMB 13.8M
- SNGX 13.8M
- IPO Year
- CMMB N/A
- SNGX 1987
- Fundamental
- Price
- CMMB $2.54
- SNGX $1.47
- Analyst Decision
- CMMB Strong Buy
- SNGX Strong Buy
- Analyst Count
- CMMB 2
- SNGX 1
- Target Price
- CMMB $26.50
- SNGX $6.00
- AVG Volume (30 Days)
- CMMB 80.5K
- SNGX 267.9K
- Earning Date
- CMMB 11-20-2025
- SNGX 11-07-2025
- Dividend Yield
- CMMB N/A
- SNGX N/A
- EPS Growth
- CMMB N/A
- SNGX N/A
- EPS
- CMMB N/A
- SNGX N/A
- Revenue
- CMMB N/A
- SNGX N/A
- Revenue This Year
- CMMB N/A
- SNGX N/A
- Revenue Next Year
- CMMB N/A
- SNGX N/A
- P/E Ratio
- CMMB N/A
- SNGX N/A
- Revenue Growth
- CMMB N/A
- SNGX N/A
- 52 Week Low
- CMMB $2.36
- SNGX $1.09
- 52 Week High
- CMMB $9.84
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- CMMB 42.45
- SNGX 50.09
- Support Level
- CMMB $2.36
- SNGX $1.25
- Resistance Level
- CMMB $2.85
- SNGX $1.53
- Average True Range (ATR)
- CMMB 0.20
- SNGX 0.11
- MACD
- CMMB -0.02
- SNGX 0.03
- Stochastic Oscillator
- CMMB 32.71
- SNGX 80.00
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).